The lateral flow immunoassay (lfia) based rapid test market size has declined steeply in recent years. It will grow from ' $9.19 billion in 2023 to $8.33 billion in 2024 at a compound annual growth rate (CAGR) of -9.4%. The growth observed in the historical period can be ascribed to several factors, including a surge in infectious disease cases, heightened demand for point-of-care testing within home care settings, augmented healthcare expenditure, and the expansion of emerging markets.
The lateral flow immunoassay (lfia) based rapid test market size is expected to see marginal decline in the next few years. It will grow to $7.79 billion in 2028 at a compound annual growth rate (CAGR) of -1.6%. The growth anticipated in the forecast period can be attributed to several factors, including increased healthcare access, the impact of the COVID-19 pandemic, a rising aging population, a growing demand for home-based lateral flow assay devices, enhanced accessibility, and an upswing in regulatory approvals. Noteworthy trends in the forecast period involve the advancement of technologies for multiple or repetitive LFIA-based rapid tests and the storage/communication of results. There is also a focus on forming partnerships and collaborations to introduce new or improved products, the development of at-home test kits for patients to self-administer and manage their health in their own homes, investments in artificial intelligence-based tests for disease screening and detection, and the imperative to create low-cost test kits to ensure affordable access for patients.
The lateral flow immunoassay (LFIA) based rapid test market is anticipated to witness growth driven by the demand for point-of-care testing in home care settings. Point-of-care testing is crucial for swift on-site diagnosis and treatment, with LFIA being widely used due to its speed, precision, simplicity, and cost-effectiveness. The recent COVID-19 outbreak has underscored the significance of LFIA devices for rapid screening and surveillance, as seen with products such as Acro Biotech COVID-19 Rapid POC CE-IVD and OZO's variations employing Latex Enhanced Lateral Flow Immunoassays (LFIAs) for COVID-19 testing. Consequently, the market is expected to thrive due to the need for point-of-care testing in home care settings.
The lateral flow immunoassay (LFIA) based rapid test market is set to experience growth fueled by the increasing prevalence of chronic diseases. These long-term health conditions demand early detection, point-of-care testing, and regular monitoring, with LFIA-based rapid tests offering prompt results and aiding in the management of chronic diseases. The World Health Organization reports a significant number of deaths attributed to non-communicable diseases (NCDs) annually, emphasizing the role of LFIA in addressing conditions such as cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes. The market is thus stimulated by the rising incidence of chronic diseases.
Leading companies in the lateral flow immunoassay (LFIA) based rapid test market are concentrating on innovative products to enhance their market share. Notable among these is Abbott Laboratories, which introduced the Panbio COVID-19 antigen self-test, designed for individuals to self-detect the SARS-CoV-2 virus causing COVID-19. The self-test employs Abbott's lateral flow technology, providing quick results within 15 minutes using a minimally invasive nose swab. To streamline the process, Abbott's NAVICA mobile app facilitates self-registration, result interpretation, and reporting in accordance with ICMR requirements.
The focus on healthcare investments by various stakeholders is intensifying, contributing to the lateral flow immunoassay (LFIA) based rapid test market. Such investments support research and development efforts aimed at improving LFIA test sensitivity, specificity, and overall performance. This includes the development of new LFIA assays, identification of novel biomarkers, and enhancements in detection methods. In Australia, the government has substantially increased hospital funding, reaching an estimated $32.7 billion in 2025–26, showcasing a commitment to healthcare investments.
In August 2023, Danaher Corporation acquired Abcam plc for $5.7 billion, aligning with Danaher's strategy to bolster its life sciences business. The acquisition of Abcam, a UK-based biotechnology company specializing in LFIA-based rapid tests, is expected to enhance value for shareholders and deliver outstanding results for both the workforce and clients.
Major companies operating in the lateral flow immunoassay (lfia) based rapid test market report are Abbott Laboratories, F. Hoffmann-La Roche, Quidel Corporation, Becton, Dickinson and Company, Danaher Corporation, Siemens AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., PerkinElmer Inc., Hologic, Inc., LTEK Co., Ltd., JOYSBIO Biotechnology, Jiangsu Medomics Medical Technologies, Diagnocure, Ubio Biotechnology Systems, Elabscience® Immunoassay Kits, FyoniBio / Glycotope GmbH, Atomo Diagnostics Limited, INDICAL Bioscience, Lionex Gmbh, BIOMED Labordiagnostik GmbH, Charles River Laboratories, EKF Diagnostics, Launch Diagnostics, Diagnostic Instruments Ltd., Qiagen N.V., Merck KGaA, XPhyto Therapeutics, 3a Diagnostics, Roche Holding AG, BATM, Biomaxima, SensDx, Vitrosens Biotechnology, Bioeasy Biotechnology, Fujirebio, Immunodiagnostic Systems Holdings PLC, Mesa Biotech Inc., CTK Biotech, Wamadiagnostica, Marksans Pharma Ltd., Lana Al Khaleej, Natejah Medical Supplies, Synlab, K2 Medical’s, SA Biomedical Group.
North America was the largest region in the lateral flow immunoassay (LFIA) based rapid test market in 2023. Asia-Pacific was the second largest region in the global lateral flow immunoassay (LFIA) based rapid test market. The regions covered in the lateral flow immunoassay (lfia) based rapid test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lateral flow immunoassay (lfia) based rapid test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
The primary techniques include the competitive assay, sandwich assay, and multiplex detection assay. The competitive assay specifically determines the presence of targets, such as pathogens or biomarkers, within the collected samples. Its applications span infectious diseases, pregnancy and fertility assessments, toxicology, and others, making it applicable in diverse settings such as hospitals, clinics, diagnostic laboratories, home care, and more.
The lateral flow immunoassay (LFIA) based rapid test market research report is one of a series of new reports that provides lateral flow immunoassay (LFIA) based rapid test market statistics, including lateral flow immunoassay (LFIA) based rapid test industry global market size, regional shares, competitors with a lateral flow immunoassay (LFIA) based rapid test market share, detailed lateral flow immunoassay (LFIA) based rapid test market segments, market trends and opportunities, and any further data you may need to thrive in the lateral flow immunoassay (LFIA) based rapid test industry. This lateral flow immunoassay (LFIA) based rapid test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Lateral Flow Immunoassay (LFIA) based rapid test market consists of sales of conjugate pads, nitrocellulose membrane and absorbent pad. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The lateral flow immunoassay (lfia) based rapid test market size is expected to see marginal decline in the next few years. It will grow to $7.79 billion in 2028 at a compound annual growth rate (CAGR) of -1.6%. The growth anticipated in the forecast period can be attributed to several factors, including increased healthcare access, the impact of the COVID-19 pandemic, a rising aging population, a growing demand for home-based lateral flow assay devices, enhanced accessibility, and an upswing in regulatory approvals. Noteworthy trends in the forecast period involve the advancement of technologies for multiple or repetitive LFIA-based rapid tests and the storage/communication of results. There is also a focus on forming partnerships and collaborations to introduce new or improved products, the development of at-home test kits for patients to self-administer and manage their health in their own homes, investments in artificial intelligence-based tests for disease screening and detection, and the imperative to create low-cost test kits to ensure affordable access for patients.
The lateral flow immunoassay (LFIA) based rapid test market is anticipated to witness growth driven by the demand for point-of-care testing in home care settings. Point-of-care testing is crucial for swift on-site diagnosis and treatment, with LFIA being widely used due to its speed, precision, simplicity, and cost-effectiveness. The recent COVID-19 outbreak has underscored the significance of LFIA devices for rapid screening and surveillance, as seen with products such as Acro Biotech COVID-19 Rapid POC CE-IVD and OZO's variations employing Latex Enhanced Lateral Flow Immunoassays (LFIAs) for COVID-19 testing. Consequently, the market is expected to thrive due to the need for point-of-care testing in home care settings.
The lateral flow immunoassay (LFIA) based rapid test market is set to experience growth fueled by the increasing prevalence of chronic diseases. These long-term health conditions demand early detection, point-of-care testing, and regular monitoring, with LFIA-based rapid tests offering prompt results and aiding in the management of chronic diseases. The World Health Organization reports a significant number of deaths attributed to non-communicable diseases (NCDs) annually, emphasizing the role of LFIA in addressing conditions such as cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes. The market is thus stimulated by the rising incidence of chronic diseases.
Leading companies in the lateral flow immunoassay (LFIA) based rapid test market are concentrating on innovative products to enhance their market share. Notable among these is Abbott Laboratories, which introduced the Panbio COVID-19 antigen self-test, designed for individuals to self-detect the SARS-CoV-2 virus causing COVID-19. The self-test employs Abbott's lateral flow technology, providing quick results within 15 minutes using a minimally invasive nose swab. To streamline the process, Abbott's NAVICA mobile app facilitates self-registration, result interpretation, and reporting in accordance with ICMR requirements.
The focus on healthcare investments by various stakeholders is intensifying, contributing to the lateral flow immunoassay (LFIA) based rapid test market. Such investments support research and development efforts aimed at improving LFIA test sensitivity, specificity, and overall performance. This includes the development of new LFIA assays, identification of novel biomarkers, and enhancements in detection methods. In Australia, the government has substantially increased hospital funding, reaching an estimated $32.7 billion in 2025–26, showcasing a commitment to healthcare investments.
In August 2023, Danaher Corporation acquired Abcam plc for $5.7 billion, aligning with Danaher's strategy to bolster its life sciences business. The acquisition of Abcam, a UK-based biotechnology company specializing in LFIA-based rapid tests, is expected to enhance value for shareholders and deliver outstanding results for both the workforce and clients.
Major companies operating in the lateral flow immunoassay (lfia) based rapid test market report are Abbott Laboratories, F. Hoffmann-La Roche, Quidel Corporation, Becton, Dickinson and Company, Danaher Corporation, Siemens AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., PerkinElmer Inc., Hologic, Inc., LTEK Co., Ltd., JOYSBIO Biotechnology, Jiangsu Medomics Medical Technologies, Diagnocure, Ubio Biotechnology Systems, Elabscience® Immunoassay Kits, FyoniBio / Glycotope GmbH, Atomo Diagnostics Limited, INDICAL Bioscience, Lionex Gmbh, BIOMED Labordiagnostik GmbH, Charles River Laboratories, EKF Diagnostics, Launch Diagnostics, Diagnostic Instruments Ltd., Qiagen N.V., Merck KGaA, XPhyto Therapeutics, 3a Diagnostics, Roche Holding AG, BATM, Biomaxima, SensDx, Vitrosens Biotechnology, Bioeasy Biotechnology, Fujirebio, Immunodiagnostic Systems Holdings PLC, Mesa Biotech Inc., CTK Biotech, Wamadiagnostica, Marksans Pharma Ltd., Lana Al Khaleej, Natejah Medical Supplies, Synlab, K2 Medical’s, SA Biomedical Group.
North America was the largest region in the lateral flow immunoassay (LFIA) based rapid test market in 2023. Asia-Pacific was the second largest region in the global lateral flow immunoassay (LFIA) based rapid test market. The regions covered in the lateral flow immunoassay (lfia) based rapid test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lateral flow immunoassay (lfia) based rapid test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
The primary techniques include the competitive assay, sandwich assay, and multiplex detection assay. The competitive assay specifically determines the presence of targets, such as pathogens or biomarkers, within the collected samples. Its applications span infectious diseases, pregnancy and fertility assessments, toxicology, and others, making it applicable in diverse settings such as hospitals, clinics, diagnostic laboratories, home care, and more.
The lateral flow immunoassay (LFIA) based rapid test market research report is one of a series of new reports that provides lateral flow immunoassay (LFIA) based rapid test market statistics, including lateral flow immunoassay (LFIA) based rapid test industry global market size, regional shares, competitors with a lateral flow immunoassay (LFIA) based rapid test market share, detailed lateral flow immunoassay (LFIA) based rapid test market segments, market trends and opportunities, and any further data you may need to thrive in the lateral flow immunoassay (LFIA) based rapid test industry. This lateral flow immunoassay (LFIA) based rapid test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Lateral Flow Immunoassay (LFIA) based rapid test market consists of sales of conjugate pads, nitrocellulose membrane and absorbent pad. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Characteristics3. Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Trends and Strategies32. Global Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Competitive Benchmarking33. Global Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Competitive Dashboard34. Key Mergers and Acquisitions in the Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
4. Lateral Flow Immunoassay (LFIA) Based Rapid Test Market - Macro Economic Scenario
5. Global Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Size and Growth
6. Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Segmentation
7. Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Regional and Country Analysis
8. Asia-Pacific Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
9. China Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
10. India Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
11. Japan Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
12. Australia Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
13. Indonesia Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
14. South Korea Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
15. Western Europe Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
16. UK Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
17. Germany Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
18. France Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
19. Italy Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
20. Spain Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
21. Eastern Europe Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
22. Russia Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
23. North America Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
24. USA Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
25. Canada Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
26. South America Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
27. Brazil Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
28. Middle East Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
29. Africa Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
30. Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Competitive Landscape and Company Profiles
31. Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Other Major and Innovative Companies
35. Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Lateral Flow Immunoassay (LFIA) Based Rapid Test Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on lateral flow immunoassay (lfia) based rapid test market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for lateral flow immunoassay (lfia) based rapid test? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Technique: Competitive Assay; Sandwich Assay; Multiplex Detection Assay
2) By Application: Infectious Disease; Pregnancy and Fertility; Toxicology; Cardiac Marker and Cholesterol Testing; Other Applications
3) By End-Users: Hospitals and Clinics; Diagnostic Laboratories; Home Care; Other End-users
Key Companies Mentioned: Abbott Laboratories; F. Hoffmann-La Roche; Quidel Corporation; Becton, Dickinson and Company; Danaher Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Abbott Laboratories
- F. Hoffmann-La Roche
- Quidel Corporation
- Becton, Dickinson and Company
- Danaher Corporation
- Siemens AG
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories, Inc.
- PerkinElmer Inc.
- Hologic, Inc.
- LTEK Co., Ltd.
- JOYSBIO Biotechnology
- Jiangsu Medomics Medical Technologies
- Diagnocure
- Ubio Biotechnology Systems
- Elabscience® Immunoassay Kits
- FyoniBio / Glycotope GmbH
- Atomo Diagnostics Limited
- INDICAL Bioscience
- Lionex Gmbh
- BIOMED Labordiagnostik GmbH
- Charles River Laboratories
- EKF Diagnostics
- Launch Diagnostics
- Diagnostic Instruments Ltd
- Qiagen N.V.
- Merck KGaA
- XPhyto Therapeutics
- 3a Diagnostics
- Roche Holding AG
- BATM
- Biomaxima
- SensDx
- Vitrosens Biotechnology
- Bioeasy Biotechnology
- Fujirebio
- Immunodiagnostic Systems Holdings PLC
- Mesa Biotech Inc
- CTK Biotech
- Wamadiagnostica
- Marksans Pharma Ltd
- Lana Al Khaleej
- Natejah Medical Supplies
- Synlab
- K2 Medical’s
- SA Biomedical Group
Methodology
LOADING...
